Rxivist logo

Treatment of Graft-versus-Host Disease by Echinomycin in a New Humanized Mouse Model

By Yan Liu, Christopher Bailey, Christopher Lazarski, Chun-shu Wong, Pan Zheng, Yang Liu, Yin Wang

Posted 16 Feb 2017
bioRxiv DOI: 10.1101/108951

Drug development effort against GVHD is hampered by the lack of clinically relevant humanized animal models for preclinical testing. Current humanized GVHD models rely on adoptive transfer of a high number of human peripheral blood mononuclear cells (PBMCs) into immunodeficient mice. Here we report a novel humanized GVHD model by transplanting a small number of human BM cells into newborn NOD.SCID IL2rγ0 (NSG) mice. Transplantation of human BM cells (BMT) causes acute GVHD, with lethality between 15 to 60 days. Pervasive human T-cell infiltration into multiple organs, including lung, intestine, skin, kidney, liver, and stomach, was observed in all mice analyzed. Surprisingly, the human T cells express high levels of hypoxia inducible factor 1α (HIF1α) protein even under normoxic environment. Administration of Echinomycin, a potent inhibitor for HIF1α, rapidly ablated HIF1α protein in T cells and gradually reduced the frequency of human cells in the peripheral blood and target organs. Echinomycin provides a sustained therapeutic effect, as demonstrated by dramatic reduction of clinical symptoms, pathology score and by doubling of the median life span of the chimeric mice. Our results reveal a critical role of HIF1α in GVHD and demonstrate that HIF1α inhibitors such as Echinomycin should be explored for clinical drug development against GVHD.

Download data

  • Downloaded 413 times
  • Download rankings, all-time:
    • Site-wide: 57,843
    • In immunology: 1,526
  • Year to date:
    • Site-wide: 53,197
  • Since beginning of last month:
    • Site-wide: 83,769

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)